NPV modelling for the selection of value-creating biosimilar development candidates
The purpose of this study was to apply net present value (NPV) modelling to evaluate the financial attractiveness and business risk of different categories of biosimilars. Challenges and opportunities of biosimilars are compared with those of standard small molecule generics. Minimum peak sales levels are required to create financial value were determined in order to derive recommendations for the selection of commercially rewarding biosimilar development candidates.
Full details at the Journal of Commercial BiotechnologyClick here for reuse options!
Copyright 2013 Biotechblog
Comments are closed.